BioVendor Group Introduces Groundbreaking Immunological Biomarker

At this year’s MEDICA, BioVendor Group (Brno, Czech Republic) is showcasing its impressive diagnostic innovations, from CLIA advancements to the groundbreaking MxA biomarker, which plays a key role in distinguishing between bacterial and viral infections.

BioVendor Group is fitting all group companies into a shared exhibition space at MEDICA 2024 and creating a welcoming environment for hundreds of meetings with new and existing business partners, customers, and suppliers. Visitors to the shared BioVendor Group booth can learn about several other product news and innovations from the companies BioVendor Research & Diagnostic Products, TestLine Clinical Diagnostics s.r.o., ViennaLab Diagnostics, DIAsource ImmunoAssays S.A. and BioVendor MDx. The main "drivers" are again the key projects CLIA, MBA, and NGS, developed in synergy by the various companies of the BioVendor Group. BioVendor is introducing brand-new micro-array kits from TestLine Clinical Diagnostics for the diagnosis of liver and gastrointestinal autoimmune diseases. Also featuring at the show is BioVendor MDx’s NGS fastGEN technology which offers rapid and accurate genetic analysis, enabling efficient cancer diagnostics. BioVendor MDx’s fastGEN BCR::ABL1 cancer kit specifically detects fusion genes associated with leukemia, supporting early diagnosis and treatment management. In addition to these innovations, visitors can also learn more about BioVendor MDx’s bioinformatics solution GENOVESA which is designed for seamless data interpretation and reporting.

DIAsource is announcing the addition of a new rapid test (POCT) and its respective reader to the company’s portfolio. These products complete the company’s panel with additional technologies and interesting parameters in the fields of women’s health, tumor markers, drugs of abuse, infectious diseases, cardiac markers. DIAsource is also launching a series of new antibodies in the fields of Alzheimer's disease, cardiac markers, diabetes and fertility. These antibodies have proven to be reliable raw materials in the manufacturing of immunoassays such as CLIA, ELISA, FIA, and POCT. BioVendor RnD is showcasing its extensive portfolio of ELISA kits for both research and diagnostic applications. In addition to its high-quality ELISA kits, the company is highlighting its high-purity proteins and a broad range of antibodies. BioVendor RnD is also presenting the MxA Point-of-Care-Test designed for the rapid differentiation between bacterial and viral infections. Visitors to the shared BioVendor Group booth can also learn about ViennaLab’s upcoming SMA RealFast Assay, comprehensive OncNGS (liquid biopsy (cfDNA) NGS solution), 16S Microbiome + ITS NGS Assay.

Related Links:
BioVendor Group